49679-41-6

Upstream product

• 1204-75-7 3-hydroxyquinoxaline-2-carboxylic acid 
• 20254-76-6 3-Chloroquinoxaline-2-carboxylic acid 

Downstream Products

• 1186470-03-0 C₁₇H₁₁ClN₄O 
• 1186470-08-5 C₁₆H₁₁ClN₄O₃ 
• 1186468-98-3 3-amino-N-((2-chloro-6-methylphenyl)methyl)-2-quinoxalinecarboxamide 
• 1621109-03-2 3-chloro-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide 
• 1621108-62-0 3-(2,4-difluorophenoxy)-N-(3-sulfamoylphenyl)quinoxaline-2-carboxamide 
• 1621109-00-9 tert-butyl 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)benzoate 
• 1621108-33-5 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)benzoic acid 
• 1621108-32-4 4-(3-(4-(trifluoromethoxy)phenoxy)quinoxaline-2-carboxamido)picolinic acid 
• 1621108-16-4 5-(3-(2,4-dimethoxyphenoxy)quinoxaline-2-carboxamido)picolinic acid 
• 1621108-99-3 tert-butyl 4-[(3-chloroquinoxaline-2-carbonyl)amino]benzoate 
• 1422642-91-8 1-(3-chloroquinoxalin-2-yl)-3-phenylprop-2-yn-1-one 
• 1422642-92-9 3-(4-tert-butylphenyl)-1-(3-chloroquinoxalin-2-yl)prop-2-yn-1-one 
• 1422642-94-1 1-cyclohexyl-2-phenylpyrido[2,3-b]quinoxalin-4(1H)-one 
• 1422643-06-8 2-octyl-1-phenethylpyrido[2,3-b]quinoxalin-4(1H)-one 

Relevant academic research and scientific papers

QUINOLINE AND QUINAZOLINE AMIDES AS MODULATORS OF SODIUM CHANNELS

The invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: formula (I). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the inve

Efficient synthesis of novel benzo[b][1,8]naphthyridin-4(1H)-ones and pyrido[2,3-b]quinoxalin-4(1H)-ones from alkynones and primary amines

An efficient palladium-catalyzed cyclization of o-chlorohetaryl ynones with aliphatic and aromatic primary amines represents a simple access to a wide range of benzo[b][1,8]naphthyridin-4(1H)-one and pyrido[2,3-b]quinoxalin-4(1H)- one derivatives in good to excellent yields.

INHIBITORS OF FATTY ACID BINDING PROTEIN

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS

Compounds of the Formula (I), where W represents CH or N; and Q represents -CN, -C(=NOH)NH2, -CONHR1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson''s disease.

Pyrazolo[4′,3′:5,6]pyrano[2,3-b]quinoxalin-4(1H)-one: Synthesis and characterization of a novel tetracyclic ring system

(Chemical Equation Presented) Derivatives of the hitherto unknown ring system, pyrazolo[4′,3′:5,6]pyrano[2,3-b]quinoxalin-4(1H)-one, are synthesized in one step from the corresponding 1-substuituted or 1,3-disubstituted 2-pyrazolin-5-ones and 3-chloroquinoxaline-2-carbonyl chloride using calcium hydroxide in boiling 1,4-dioxane. The parent system carrying no substituent in positions 1 and 3 is obtained upon treatment of the 1-PMB (p-methoxybenzyl) protected congener with trifluoroacetic acid. Detailed NMR spectroscopic investigations including unambiguous chemical shift assignments of all 1H, 13C, and 15N resonances of the obtained tetracycles are reported.